Darunavir, Ritonavir, Truvada — Competitive Intelligence Brief

Darunavir, Ritonavir, Truvada (Darunavir, Ritonavir, Truvada) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors) HIV protease, HIV reverse transcriptase, CYP3A4 Infectious Disease / Virology Small molecule

Target snapshot

Darunavir, Ritonavir, Truvada (Darunavir, Ritonavir, Truvada) — Imperial College London. This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Darunavir, Ritonavir, Truvada TARGET	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
darunavir; ritonavir; emtricitabine/tenofovir	darunavir; ritonavir; emtricitabine/tenofovir	ANRS, Emerging Infectious Diseases	phase 3	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors) class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Imperial College London · 1 drug in this class